In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies

Ali Mahtabifard, Robert E. Merritt, Reiko E. Yamada, Ronald Crystal, Robert J. Korst

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective: Pigment epithelium-derived factor is known to be an inhibitor of angiogenesis. We hypothesized that in vivo gene transfer of pigment epithelium-derived factor may inhibit tumor angiogenesis and growth in syngeneic models of thoracic malignancies. Methods: An adenovirus vector encoding the human pigment epithelium-derived factor cDNA (AdPEDF) was used to transduce human lung cancer cells in vitro. Transgene expression was assessed using Western analysis. Three different murine flank tumors (2 lung, 1 colon) were then established in syngeneic mice and treated intratumorally with phosphate-buffered saline, AdPEDF, or an empty vector (Ad-Null). Endpoints measured included transgene expression, tumor size, and animal survival, as well as microvessel density within the tumor. Additionally, a murine pulmonary metastasis model was established by intravenous injection of a syngeneic colon adenocarcinoma cell line expressing a marker gene (β-galactosidase). One day later, treatment (phosphate-buffered saline, AdNull, or AdPEDF) was administered intrapleurally. Tumor burden (gross and histologic inspection, lung weight, and β-galactosidase expression) was then evaluated 13 days after vector dosing, and survival was recorded. Results: AdPEDF-derived expression of pigment epithelium-derived factor was demonstrated in vitro and in vivo. In syngeneic murine lung cancer flank tumors, intratumoral administration of AdPEDF significantly inhibited tumor growth (P < .01), prolonged mouse survival (P < .01), and decreased microvessel density (P < .01) compared with control groups. In the pulmonary metastasis model, AdPEDF-treated mice exhibited significantly reduced lung lesions, lung weight (P < .0005), β-galactosidase expression (P < .05), and animal survival was prolonged (P < .05). Conclusion: Gene transfer of pigment epithelium-derived factor suppresses tumor vascularization and growth, while prolonging survival in syngeneic murine models of thoracic malignancies.

Original languageEnglish
Pages (from-to)28-38
Number of pages11
JournalJournal of Thoracic and Cardiovascular Surgery
Volume126
Issue number1
DOIs
Publication statusPublished - 1 Jul 2003
Externally publishedYes

Fingerprint

Thorax
Galactosidases
Growth
Genes
Neoplasms
Lung
Microvessels
Transgenes
Lung Neoplasms
Colon
Phosphates
Neoplasm Metastasis
pigment epithelium-derived factor
Weights and Measures
Angiogenesis Inhibitors
Tumor Burden
Adenoviridae
Intravenous Injections
Adenocarcinoma
Complementary DNA

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. / Mahtabifard, Ali; Merritt, Robert E.; Yamada, Reiko E.; Crystal, Ronald; Korst, Robert J.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 126, No. 1, 01.07.2003, p. 28-38.

Research output: Contribution to journalArticle

@article{50743ca3e3354da58493f4c4431754ca,
title = "In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies",
abstract = "Objective: Pigment epithelium-derived factor is known to be an inhibitor of angiogenesis. We hypothesized that in vivo gene transfer of pigment epithelium-derived factor may inhibit tumor angiogenesis and growth in syngeneic models of thoracic malignancies. Methods: An adenovirus vector encoding the human pigment epithelium-derived factor cDNA (AdPEDF) was used to transduce human lung cancer cells in vitro. Transgene expression was assessed using Western analysis. Three different murine flank tumors (2 lung, 1 colon) were then established in syngeneic mice and treated intratumorally with phosphate-buffered saline, AdPEDF, or an empty vector (Ad-Null). Endpoints measured included transgene expression, tumor size, and animal survival, as well as microvessel density within the tumor. Additionally, a murine pulmonary metastasis model was established by intravenous injection of a syngeneic colon adenocarcinoma cell line expressing a marker gene (β-galactosidase). One day later, treatment (phosphate-buffered saline, AdNull, or AdPEDF) was administered intrapleurally. Tumor burden (gross and histologic inspection, lung weight, and β-galactosidase expression) was then evaluated 13 days after vector dosing, and survival was recorded. Results: AdPEDF-derived expression of pigment epithelium-derived factor was demonstrated in vitro and in vivo. In syngeneic murine lung cancer flank tumors, intratumoral administration of AdPEDF significantly inhibited tumor growth (P < .01), prolonged mouse survival (P < .01), and decreased microvessel density (P < .01) compared with control groups. In the pulmonary metastasis model, AdPEDF-treated mice exhibited significantly reduced lung lesions, lung weight (P < .0005), β-galactosidase expression (P < .05), and animal survival was prolonged (P < .05). Conclusion: Gene transfer of pigment epithelium-derived factor suppresses tumor vascularization and growth, while prolonging survival in syngeneic murine models of thoracic malignancies.",
author = "Ali Mahtabifard and Merritt, {Robert E.} and Yamada, {Reiko E.} and Ronald Crystal and Korst, {Robert J.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1016/S0022-5223(02)73616-7",
language = "English",
volume = "126",
pages = "28--38",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies

AU - Mahtabifard, Ali

AU - Merritt, Robert E.

AU - Yamada, Reiko E.

AU - Crystal, Ronald

AU - Korst, Robert J.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Objective: Pigment epithelium-derived factor is known to be an inhibitor of angiogenesis. We hypothesized that in vivo gene transfer of pigment epithelium-derived factor may inhibit tumor angiogenesis and growth in syngeneic models of thoracic malignancies. Methods: An adenovirus vector encoding the human pigment epithelium-derived factor cDNA (AdPEDF) was used to transduce human lung cancer cells in vitro. Transgene expression was assessed using Western analysis. Three different murine flank tumors (2 lung, 1 colon) were then established in syngeneic mice and treated intratumorally with phosphate-buffered saline, AdPEDF, or an empty vector (Ad-Null). Endpoints measured included transgene expression, tumor size, and animal survival, as well as microvessel density within the tumor. Additionally, a murine pulmonary metastasis model was established by intravenous injection of a syngeneic colon adenocarcinoma cell line expressing a marker gene (β-galactosidase). One day later, treatment (phosphate-buffered saline, AdNull, or AdPEDF) was administered intrapleurally. Tumor burden (gross and histologic inspection, lung weight, and β-galactosidase expression) was then evaluated 13 days after vector dosing, and survival was recorded. Results: AdPEDF-derived expression of pigment epithelium-derived factor was demonstrated in vitro and in vivo. In syngeneic murine lung cancer flank tumors, intratumoral administration of AdPEDF significantly inhibited tumor growth (P < .01), prolonged mouse survival (P < .01), and decreased microvessel density (P < .01) compared with control groups. In the pulmonary metastasis model, AdPEDF-treated mice exhibited significantly reduced lung lesions, lung weight (P < .0005), β-galactosidase expression (P < .05), and animal survival was prolonged (P < .05). Conclusion: Gene transfer of pigment epithelium-derived factor suppresses tumor vascularization and growth, while prolonging survival in syngeneic murine models of thoracic malignancies.

AB - Objective: Pigment epithelium-derived factor is known to be an inhibitor of angiogenesis. We hypothesized that in vivo gene transfer of pigment epithelium-derived factor may inhibit tumor angiogenesis and growth in syngeneic models of thoracic malignancies. Methods: An adenovirus vector encoding the human pigment epithelium-derived factor cDNA (AdPEDF) was used to transduce human lung cancer cells in vitro. Transgene expression was assessed using Western analysis. Three different murine flank tumors (2 lung, 1 colon) were then established in syngeneic mice and treated intratumorally with phosphate-buffered saline, AdPEDF, or an empty vector (Ad-Null). Endpoints measured included transgene expression, tumor size, and animal survival, as well as microvessel density within the tumor. Additionally, a murine pulmonary metastasis model was established by intravenous injection of a syngeneic colon adenocarcinoma cell line expressing a marker gene (β-galactosidase). One day later, treatment (phosphate-buffered saline, AdNull, or AdPEDF) was administered intrapleurally. Tumor burden (gross and histologic inspection, lung weight, and β-galactosidase expression) was then evaluated 13 days after vector dosing, and survival was recorded. Results: AdPEDF-derived expression of pigment epithelium-derived factor was demonstrated in vitro and in vivo. In syngeneic murine lung cancer flank tumors, intratumoral administration of AdPEDF significantly inhibited tumor growth (P < .01), prolonged mouse survival (P < .01), and decreased microvessel density (P < .01) compared with control groups. In the pulmonary metastasis model, AdPEDF-treated mice exhibited significantly reduced lung lesions, lung weight (P < .0005), β-galactosidase expression (P < .05), and animal survival was prolonged (P < .05). Conclusion: Gene transfer of pigment epithelium-derived factor suppresses tumor vascularization and growth, while prolonging survival in syngeneic murine models of thoracic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0042844689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042844689&partnerID=8YFLogxK

U2 - 10.1016/S0022-5223(02)73616-7

DO - 10.1016/S0022-5223(02)73616-7

M3 - Article

C2 - 12878936

AN - SCOPUS:0042844689

VL - 126

SP - 28

EP - 38

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 1

ER -